Impact of metabolic syndrome in patients with psoriatic arthritis in a cohort from the province of Córdoba
Psoriatic arthritis (PsA) is associated with higher cardiovascular morbidity and mortality than the general population. Metabolic syndrome (MetS) induces a proinflammatory state that could affect the activity of the disease and the treatment response. Our objective was to describe and compa...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2023
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/42708 |
| Aporte de: |
| id |
I10-R327-article-42708 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| language |
Español |
| format |
Artículo revista |
| topic |
psoriatic arthritis Metabolic Syndrome cardiovascular risk Artritis psoriasica Síndrome metabólico Riesgo cardiovascular |
| spellingShingle |
psoriatic arthritis Metabolic Syndrome cardiovascular risk Artritis psoriasica Síndrome metabólico Riesgo cardiovascular Figueroa, RM Albiero , JA Gobbi, C Demarchi, M Alonso, C Alba, P Savio , V Impact of metabolic syndrome in patients with psoriatic arthritis in a cohort from the province of Córdoba |
| topic_facet |
psoriatic arthritis Metabolic Syndrome cardiovascular risk Artritis psoriasica Síndrome metabólico Riesgo cardiovascular |
| author |
Figueroa, RM Albiero , JA Gobbi, C Demarchi, M Alonso, C Alba, P Savio , V |
| author_facet |
Figueroa, RM Albiero , JA Gobbi, C Demarchi, M Alonso, C Alba, P Savio , V |
| author_sort |
Figueroa, RM |
| title |
Impact of metabolic syndrome in patients with psoriatic arthritis in a cohort from the province of Córdoba |
| title_short |
Impact of metabolic syndrome in patients with psoriatic arthritis in a cohort from the province of Córdoba |
| title_full |
Impact of metabolic syndrome in patients with psoriatic arthritis in a cohort from the province of Córdoba |
| title_fullStr |
Impact of metabolic syndrome in patients with psoriatic arthritis in a cohort from the province of Córdoba |
| title_full_unstemmed |
Impact of metabolic syndrome in patients with psoriatic arthritis in a cohort from the province of Córdoba |
| title_sort |
impact of metabolic syndrome in patients with psoriatic arthritis in a cohort from the province of córdoba |
| description |
Psoriatic arthritis (PsA) is associated with higher cardiovascular morbidity and mortality than the general population. Metabolic syndrome (MetS) induces a proinflammatory state that could affect the activity of the disease and the treatment response. Our objective was to describe and compare the presence of MetS in patients with Psoriatic Arthritis (PsA) and its relationship with disease activity, quality of life, and treatment.
A prospective cross-sectional study was performed at Cordoba Hospital between 07/2019 to 03/2022. Patients older than 18 years old with a diagnosis of PsA according to (CASPAR criteria) were included. Sociodemographic and clinical features were analyzed and disease activity was evaluated by PASI (psoriasis area severity index), DAPSA (disease activity for psoriatic arthritis), MDA and VLDA (minimal and very low disease activity). Quality of life was assessed by self-administered questionnaires: DLQI (Dermatology life quality index), PASQoL (Psoriatic Arthritis Quality of Life) and HAQ (Health assessment questionnaire). MetS was defined by WHO, ATPIII, and IDF criteria. p<0.05 significant. The study was approved by ethical committee of Cordoba Hospital.
69 patients with PsA, were included with a median age of 55.92±9.88 years. 60%were female. 39% of patients fulfilled MetS criteria by WHO, 70% by IDF and 37% by ATPIII. >80% of patients of both groups had polyarticular involvement. Patients with MetS had a higher frequency of hypertension, diabetes, dyslipidemia, and ischemic heart disease (p<0.05). Remission was achieved by DAPSA in 4% of those with MetS versus 14% without MetS; MDA 28% versus 40% and VLDA 4% and 12% respectively (p=NS), DLQI in MetS and without MetS was (7.65±6.18 vs 9.72±7.83: p>0.05) and PASQUoL (10.04±4.49 vs 8.3±5.32; p>0 .05). Patients with MetS had a higher HAQ (1.08±0.61 vs 0.73±0.66; p<0.05). Treatment was not different between the two groups.
The presence of MetS in PsA was associated with cardio metabolic comorbidities and worse quality of life. A multidisciplinary approach is essential in this group of patients in order to reduce cardiovascular morbidity and mortality. |
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2023 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/42708 |
| work_keys_str_mv |
AT figueroarm impactofmetabolicsyndromeinpatientswithpsoriaticarthritisinacohortfromtheprovinceofcordoba AT albieroja impactofmetabolicsyndromeinpatientswithpsoriaticarthritisinacohortfromtheprovinceofcordoba AT gobbic impactofmetabolicsyndromeinpatientswithpsoriaticarthritisinacohortfromtheprovinceofcordoba AT demarchim impactofmetabolicsyndromeinpatientswithpsoriaticarthritisinacohortfromtheprovinceofcordoba AT alonsoc impactofmetabolicsyndromeinpatientswithpsoriaticarthritisinacohortfromtheprovinceofcordoba AT albap impactofmetabolicsyndromeinpatientswithpsoriaticarthritisinacohortfromtheprovinceofcordoba AT saviov impactofmetabolicsyndromeinpatientswithpsoriaticarthritisinacohortfromtheprovinceofcordoba AT figueroarm impactodelsindromemetabolicoenunacohortedepacientesconartritispsoriasicadelaprovinciadecordoba AT albieroja impactodelsindromemetabolicoenunacohortedepacientesconartritispsoriasicadelaprovinciadecordoba AT gobbic impactodelsindromemetabolicoenunacohortedepacientesconartritispsoriasicadelaprovinciadecordoba AT demarchim impactodelsindromemetabolicoenunacohortedepacientesconartritispsoriasicadelaprovinciadecordoba AT alonsoc impactodelsindromemetabolicoenunacohortedepacientesconartritispsoriasicadelaprovinciadecordoba AT albap impactodelsindromemetabolicoenunacohortedepacientesconartritispsoriasicadelaprovinciadecordoba AT saviov impactodelsindromemetabolicoenunacohortedepacientesconartritispsoriasicadelaprovinciadecordoba |
| first_indexed |
2024-09-03T21:04:51Z |
| last_indexed |
2024-09-03T21:04:51Z |
| _version_ |
1809210399600410624 |
| spelling |
I10-R327-article-427082023-10-19T21:19:47Z Impact of metabolic syndrome in patients with psoriatic arthritis in a cohort from the province of Córdoba Impacto del síndrome metabólico en una cohorte de pacientes con artritis psoriásica de la provincia de Córdoba Figueroa, RM Albiero , JA Gobbi, C Demarchi, M Alonso, C Alba, P Savio , V psoriatic arthritis Metabolic Syndrome cardiovascular risk Artritis psoriasica Síndrome metabólico Riesgo cardiovascular Psoriatic arthritis (PsA) is associated with higher cardiovascular morbidity and mortality than the general population. Metabolic syndrome (MetS) induces a proinflammatory state that could affect the activity of the disease and the treatment response. Our objective was to describe and compare the presence of MetS in patients with Psoriatic Arthritis (PsA) and its relationship with disease activity, quality of life, and treatment. A prospective cross-sectional study was performed at Cordoba Hospital between 07/2019 to 03/2022. Patients older than 18 years old with a diagnosis of PsA according to (CASPAR criteria) were included. Sociodemographic and clinical features were analyzed and disease activity was evaluated by PASI (psoriasis area severity index), DAPSA (disease activity for psoriatic arthritis), MDA and VLDA (minimal and very low disease activity). Quality of life was assessed by self-administered questionnaires: DLQI (Dermatology life quality index), PASQoL (Psoriatic Arthritis Quality of Life) and HAQ (Health assessment questionnaire). MetS was defined by WHO, ATPIII, and IDF criteria. p<0.05 significant. The study was approved by ethical committee of Cordoba Hospital. 69 patients with PsA, were included with a median age of 55.92±9.88 years. 60%were female. 39% of patients fulfilled MetS criteria by WHO, 70% by IDF and 37% by ATPIII. >80% of patients of both groups had polyarticular involvement. Patients with MetS had a higher frequency of hypertension, diabetes, dyslipidemia, and ischemic heart disease (p<0.05). Remission was achieved by DAPSA in 4% of those with MetS versus 14% without MetS; MDA 28% versus 40% and VLDA 4% and 12% respectively (p=NS), DLQI in MetS and without MetS was (7.65±6.18 vs 9.72±7.83: p>0.05) and PASQUoL (10.04±4.49 vs 8.3±5.32; p>0 .05). Patients with MetS had a higher HAQ (1.08±0.61 vs 0.73±0.66; p<0.05). Treatment was not different between the two groups. The presence of MetS in PsA was associated with cardio metabolic comorbidities and worse quality of life. A multidisciplinary approach is essential in this group of patients in order to reduce cardiovascular morbidity and mortality. La artritis psoriásica (APs) se asocia a mayor morbimortalidad cardiovascular que la población general. Dentro de las patologías concomitantes, el síndrome metabólico (SMet) produce un estado proinflamatorio que podría afectar la actividad de la enfermedad y la respuesta al tratamiento. Nuestro objetivo fue describir y comparar la presencia de SMet en pacientes con Artritis Psoriásica (APs), analizando su relación con la actividad de la enfermedad, calidad de vida y tratamiento. Se realizó un estudio prospectivo de corte transversal, realizado entre 07/2019-03/2022. Ingresaron pacientes mayores de 18 años, con diagnóstico de APs (criterios CASPAR). Se evaluaron características sociodemográficas y clínicas, la actividad de la enfermedad por PASI (psoriasis area severity index), DAPSA (disease activity for psoriatic arthritis), MDA y VLDA (minimal y very low disease activity); calidad de vida por cuestionarios autoadministrados: DLQI (Dermatology life quality index), PASQoL (Psoriatic Arthritis Quality of Life) y HAQ (Health assessment questionnaire). El SMet fue definido utilizando las 3 definiciones: WHO, ATPIII, IDF. Para el análisis entre grupos se utilizó ATPIII. Se aplicaron test paramétricos y no paramétricos, considerando un valor de p<0,05 significativo. El estudio tiene aprobación del CIEIS del Hospital Córdoba y no presenta conflictos de interés. Se incluyeron 69 pacientes con APs, con una mediana de 55,92±9,88 años. 60% sexo femenino. Presentaron SMet el 39% (OMS), 70% (IDF) y 37% (ATPIII). La afectación más frecuente fue poliarticular (>80%) en ambos grupos. Los pacientes con SMet presentaron mayor frecuencia de hipertensión, diabetes, dislipemia y cardiopatía isquémica (p<0,05). Lograron remisión por DAPSA el 4% de los con SMet versus el 14% de aquellos que no lo tenían; MDA el 28% versus 40% y VLDA el 4% y 12%, sin significancia estadística. Lo mismo ocurrió para DLQI (7,65±6,18 vs 9,72±7,83: p>0,05) y PASQUoL (10,04±4,49 vs 8,3±5,32; p>0,05). Los pacientes con SMet presentaron significativamente mayor HAQ (1,08±0,61 vs 0,73±0,66; p<0,05). No se encontraron diferencias en el tratamiento entre ambos grupos. Los pacientes del presente estudio con APs y SMet asociado, presentaron mayores comorbilidades cardiometabólicas junto a una peor calidad de vida. Es fundamental el abordaje multidisciplinario en este grupo de pacientes para lograr disminuir la morbimortalidad cardiovascular. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2023-10-19 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf https://revistas.unc.edu.ar/index.php/med/article/view/42708 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 80 (2023): Suplemento JIC XXIV Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 80 (2023): Suplemento JIC XXIV Revista da Faculdade de Ciências Médicas de Córdoba; v. 80 (2023): Suplemento JIC XXIV 1853-0605 0014-6722 spa https://revistas.unc.edu.ar/index.php/med/article/view/42708/42777 Derechos de autor 2023 Universidad Nacional de Córdoba http://creativecommons.org/licenses/by-nc/4.0 |